Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment

April 14, 2020—The American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) jointly developed this new guidance to detail critical cardiovascular considerations in the use of hydroxychloroquine and azithromycin for the treatment of COVID-19. The statement also includes a table rating potential adverse cardiac events of medications repurposed for COVID-19 treatment, such as chloroquine and lopinavir/ritonavir (antimalarial and antiviral agents, respectively).

 Recommended Resources: HRS COVID-19 Challenges & Solutions

Clinical EP